Eli Lilly Issues Bonds Worth $4.96 Billion

Details

The bonds include 4.150% Notes due 2027, 4.200% Notes due 2029, 4.600% Notes due 2034, 5.050% Notes due 2054, and 5.200% Notes due 2064. The proceeds were realized after deducting underwriting discounts and before estimated offering expenses. The bond issuance is pursuant to an Indenture dated February 1, 1991, and includes various exhibits detailing the terms and forms of the bonds.

Items reported

Exhibits (4)

About Eli Lilly and Company

Eli Lilly and Company is a renowned pharmaceutical corporation that engages in the discovery, development, manufacturing, and marketing of pharmaceutical products worldwide. The company's core purpose is to create high-quality medications that address significant medical needs in areas such as oncology, immunology, neuroscience, and endocrinology. Eli Lilly is particularly noted for its pioneering work in diabetes care with products like insulin and for its innovative approach to treating complex health conditions. With a history dating back to 1876, the Indianapolis-based company blends scientific innovation with a commitment to improve patient outcomes. Eli Lilly’s role in the financial markets is significant due to its contributions to healthcare advancements and its influence on global pharmaceutical trends. The company's robust pipeline and emphasis on research and development underscore its potential to impact healthcare solutions and deliver sustainable growth. Its products and services are marketed globally, underlying its importance in the biopharmaceutical industry.